The Swiss Bridge Award Goes to Researchers in St. Gallen and Vienna
Published: Tuesday, Oct 24th 2023, 16:50
Zurück zu Live Feed
Two cancer research projects from Switzerland and Austria have been awarded the Swiss-Bridge Award. Each project will receive a prize of 250,000 Swiss francs to help better understand the development of therapy resistance in cancer. Lukas Flatz from the Kantonsspital St. Gallen and his research team are looking for markers that indicate resistance in skin cancer. They have found evidence that a process called tumour differentiation may be responsible for the resistance of a new therapy for certain types of skin cancer. The second awarded project, led by Anna Christina Obenauf from the Research Institute of Molecular Pathology in Vienna, is investigating therapy resistance in lung cancer. The project aims to study a certain type of cancer cells that survive therapeutic treatment and become resistant to it, known as persister cells. Most cancer patients initially respond well to their therapies, but over time, resistance to these treatments can develop, leading to the treatments no longer working and the cancer spreading uncontrollably in the body. The exact causes and how such therapy resistance develops are not yet fully understood, which is why Swiss Bridge chose these projects.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic